Skip to main content

Table 1 Parameters indicative of Leishmania major amastigote viability and infectivity to J774A.1 in the crude ES, fractionated larval ES and Glucantime treatments

From: Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions

Treatment

Dosage (μg/ml)

Infected cells (%)

Viability of amastigotes (%)

Parasite load

Survival index

Control

0

85.37 ± 3.58

100 ± 0.00

3.19 ± 0.01

270.9 ± 1.15

Crude ES

150

41.66 ± 1.28*

30.27 ± 1.93*

1.97 ± 0.02*

82.23 ± 2.35*

 

300

32.00 ± 2.43*

20.58 ± 2.74*

1.75 ± 0.05*

53.72 ± 2.44*

> 10-kDa ES

150

58.33 ± 2.75

49.90 ± 2.71*

2.28 ± 0.03

132.99 ± 2.01*

 

300

51.00 ± 1.55*

39.46 ± 3.42*

2.10 ± 0.01*

107.33 ± 2.51*

< 10-kDa ES

150

62.66 ± 2.38

59.93 ± 2.86*

2.60 ± 0.10

162.73 ± 2.10*

 

300

55.00 ± 3.10*

49.02 ± 3.53*

2.42 ± 0.00*

133.21 ± 2.38*

Glucantime

50

39.66 ± 2.08*

28.54 ± 0.56*

1.96 ± 0.07*

77.67 ± 1.53*

 

100

30.85 ± 1.53*

15.51 ± 1.12*

1.68 ± 0.02*

51.01 ± 2.01*

  1. *P < 0.05 (significantly different from the negative control)